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Background: The Democratic Republic of the Congo (DRC) has the highest number of severe malaria cases in the
world. In early 2012, the National Malaria Control Programme (NMCP) changed the policy for treating severe malaria in
children and adults from injectable quinine to injectable artesunate. To inform the scaling up of injectable artesunate
nationwide, operational research is needed to identify constraints and challenges in the DRC’s specific setting.
Methods: The implementation of injectable quinine treatment in 350 patients aged 2 months or older in eight health
facilities from October 2012 to January 2013 and injectable artesunate in 399 patients in the same facilities from April to
June 2013 was compared. Since this was an implementation study, concurrent randomized controls were not possible.
Four key components were evaluated during each phase: 1) clinical assessment, 2) time and motion, 3) feasibility and
acceptability, and 4) financial cost.
Results: The time to discharge was lower in the artesunate (median = 2, 90 % central range 1–9) compared to the
quinine group (3 (1–9) days; p <0.001). Similarly, the interval between admission and the start of intravenous (IV)
treatment (2 (0–15) compared to 3 (0–20) hours; p <0.001) and parasite clearance time (23 (11–49) compared to 24
(10–82) hours; p <0.001) were lower in the artesunate group. The overall staff pre-administration time (13 (6–38)
compared to 20 (7–50) minutes; p <0.001) and the personnel time spent on patient management (9 (1–24)
compared to 12 (3–52) minutes; p <0.001) were lower in the artesunate group. In hospitals and health centres,
the mean (standard deviation, SD) total cost per patient treated for severe malaria with injectable artesunate was
USD 51.94 (16.20) and 19.51 (9.58); and USD 60.35 (17.73) and 20.36 (6.80) with injectable quinine.
Conclusions: This study demonstrates that injectable artesunate in the DRC is easier to use and it costs less than
injectable quinine. These findings provide the basis for practical recommendations for rapid national deployment
of injectable artesunate in the DRC.
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The Democratic Republic of the Congo (DRC) has the
highest severe malaria burden in the world [1]. The
combination of artesunate plus amodiaquine (AS-AQ)
was adopted as a first-line treatment for uncomplicated
malaria in 2005, with a second ACT, artemether plus
lumefantrine (AL), added in 2010. Meanwhile, injectable
quinine remained the recommended first-line drug for
cases of treatment failure and for severe malaria.
In 2010, the AQUAMAT trial demonstrated that treat-
ing severe malaria with artesunate reduced the case fa-
tality rate in African children (<15 years) by 22.5 %
compared to treatment with injectable quinine [2]. Pre-
viously, the benefit of artesunate compared to quinine
had been demonstrated in adults in the SEAQUAMAT
trial carried out in Southeast Asia [3]. These results led
to the recommendation of injectable artesunate as the
treatment of first choice for severe malaria in children
and adults in the WHO guidelines in 2011 [4]. Neverthe-
less, cases of delayed haemolytic anaemia secondary to in-
jectable artesunate administration were reported and the
causative role of artesunate is still controversial. Its long-
term safety profile is under evaluation. In addition to its
efficacy, injectable artesunate offers a number of program-
matic advantages over quinine, such as eliminating the
need for rate-controlled infusions or cardiac monitoring,
and the risk of induced hypoglycaemia [4].
In 2012, the National Malaria Control Programme
(NMCP) of the DRC, with support from the relevant min-
istry departments, decided to adopt the revised WHO
severe malaria treatment guidelines, which strongly rec-
ommended injectable artesunate in preference to quin-
ine or artemether as first-line treatment for severe
malaria. An implementation period of three years to
scale up injectable artesunate was included in the na-
tional strategic plan.
This transition will require many operational and clin-
ical adaptations. To support this process, there is a need
for locally derived operational experience addressing
constraints and challenges, something that all imple-
menting countries will have to consider. These data are
essential for three reasons: 1) better planning of the im-
plementation of the new treatment based on quantified
operational parameters; 2) identifying constraints and
pitfalls to guide the training of health care providers;
and, 3) providing strong and locally relevant arguments
in situations where the health staff are reluctant to
accept the change of treatment.
The present MATIAS study (‘MAlaria Treatment with
Injectable ArteSunate’) aims to support the national
introduction of injectable artesunate as the first-line
treatment of severe malaria in the DRC by assessing four
key components: 1) clinical safety, 2) time and motion,
3) feasibility and acceptability, and 4) cost.Methods
Study design
The MATIAS study was an observational implementa-
tion study of patients aged 2 months and older with
severe malaria and included two successive phases. In
the first phase, between October 2012 and January 2013,
severe malaria patients were treated with intravenous
(IV) quinine. Then, between April and June 2013, severe
malaria patients were treated with IV artesunate.
Four components were evaluated in each phase: 1)
clinical safety, assessed on the basis of limited routine
patient information; 2) time and motion parameters; 3)
feasibility and acceptability; and 4) financial costs. The
results of the feasibility and acceptability component
required additional in-depth studies and are reported
elsewhere (Ntuku et al., personal communication).Participants (population, inclusion, exclusion criteria)
The study population consisted of patients admitted
with severe malaria to one of the study sites between
October 2012 and June 2013. Patients were included in
the study if they were older than 2 months, fulfilled the
WHO criteria of severe Plasmodium falciparum malaria
[5], had either a positive rapid diagnostic test (RDT) for
P. falciparum (SD Bioline Malaria Antigen P.f/Pan
Standard Diagnostics Inc, Yongin, South Korea) and/or a
positive Giemsa-stained thick blood smear on admission,
and they or their relative or guardian gave informed
written consent. Patients were excluded if they had a
known serious adverse reaction to quinine and/or arte-
misinin derivatives, or if there was a history of adequate
anti-malarial treatment for more than 24 h before ad-
mission. Women with known or suspected pregnancy in
all trimesters during the second (artesunate) phase were
not included and were treated with quinine according to
the national guidelines [6]. Pregnancy status was deter-
mined by details from the patient’s history and/or by a
positive pregnancy test.
Signed informed consent for participation was ob-
tained in French or in the local language from all partici-
pants or from their relatives or guardians. Because of the
life-threatening nature of the disease, an initial consent
was obtained from the accompanying relative or guard-
ian on behalf of the patient, if necessary, and final
consent was solicited as soon as the patient was able to
decide and respond. Since this was an observational
study, investigators did not intervene in patient manage-
ment, which was left to the discretion of the attending
physicians. Ethical clearance for the study was obtained
from the Ethics Committee of both Cantons of Basel,
Switzerland (EKBB, Ref No 201/12) and from the Ethics
Committee of the Kinshasa School of Public Health
(KSPH Ethics Commission, Ref No 057/12), University
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Trials.gov (Identifier: NCT01828333).
Study settings
The study sites consisted of three hospitals and five health
centres in one urban and three rural health zones (HZs) in
the DRC, representative of typical health facilities in the
country (Fig. 1). The sample included a large public health
hospital (Institut Médical Evangélique, Kimpese, Bas
Congo); one medium-sized, non-profit, missionary hos-
pital (St Luc Kisantu); and a medium-sized, government
hospital (Centre Hospitalier Roi Baudouin). In addition,
five rural health centres were selected within the same
HZs (Health Centre Bita, Health Centre Menkao, Health
Centre Ngeba, Health Centre CECO, Health centre La
Famille) (Fig. 1 and Additional file 1).
Interventions
During the first phase, patients receiving IV quinine
were treated according to the national treatment guide-
lines. An initial loading dose of 20 mg of quinine salt/kg
in 5–10 ml isotonic glucose solution (5 %) per kg body
weight was infused over 4 h. Following a rest period of 8
and 12 h after administration of the loading dose began,
a maintenance dose of 10 mg of quinine salt/kg was
given. The maintenance dose was repeated every 12 h
until the patient was able to swallow the oral treatment
[5, 7]. Patients receiving artesunate (Guilin Pharmaceuti-
cals, Shanghai, China) received doses intravenously at
2.4 mg/kg on admission, at 12 and 24 h, and then once
daily until oral treatment could be swallowed [5]. TheHZ o
1 H
HZ of Kimpese
1 Hospital
2 Health Centres
Fig. 1 Map showing the location of the study sites and the selected healthcontent of each 60 mg vial of artesunate powder was dis-
solved in 1 ml of sodium bicarbonate and then diluted
with normal saline solution or dextrose 5 % before IV in-
jection [8, 9]. At least three doses of artesunate had to be
given before switching to a full course of oral treatment.
The drugs used for the study were provided for free by the
manufacturer (Artesunate, Guilin Pharmaceutical Co. Ltd,
Shanghai, China) and by the funding agency, Medicines
for Malaria Venture (MMV) (quinine).
Study outcomes
Outcome measures were defined for each of the four
study components. For the clinical assessment compo-
nent, the outcomes were: 1) duration of hospitalisation,
defined as the time from hospital registration to
discharge, (this was the primary study endpoint); 2) time
from hospital admission to start of parenteral treatment;
3) time from initiation of parenteral treatment to initi-
ation of oral treatment; 4) parasite clearance time
(PCT), defined as the time from the initiation of a
patient’s parenteral treatment until the patient’s first
negative blood film; and 5) clinical status at discharge.
For the time and motion component, the main outcome
measure was the cumulative staff time required for all
steps of drug preparation, administration and patient
management. For the feasibility and acceptability com-
ponent, the main outcomes were health-provider per-
ceived feasibility of patient management, perceived ease
of applying drug treatment, and perceived quality of case
management by patient/caretaker. These results are re-
ported separately (Ntuku et al. in prep). For the financialDem Rep Congo
HZ of Kisantu
1 Hospital 
1 Health Centre
f Masina
ospital 
HZ of Maluku
2 Health Centres
zones
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cial cost of patient management, including treatment.
Sample size calculation
The study sample size was calculated based on seven
centres, a mean hospitalisation of 2.23 days (standard
deviation of 1.64) [3], 80 % power and an assumed 20 %
shorter hospital stay with injectable artesunate. This cal-
culation yielded 25 patients per centre and study period.
Under the assumption of an effect variation by centre
with a standard deviation of 0.05, the required number
per centre was corrected to 27. This effect was pre-
sumed to be moderate, as each centre acted as its own
control in the study. The two-phase study design was se-
lected to fit the implementation strategy in this area. To
ensure a safety margin and to aid disaggregation of the
data by centre, the number of patients to be recruited
was finally set to 50 patients of all ages from each centre
and per study phase. One of the sites initially selected
was removed due to difficulties in initiating the study.
However, due to recruitment numbers slightly below ex-
pectations during the quinine phase, two additional
study centres were added. This amendment increased
the number of treatment centres to eight.
Statistical methods
Continuous outcomes were described using their mean
and standard deviation, or median and 90 % central range
if the distribution was skewed. Dichotomous outcomes
were summarized as proportions. Clinical characteristics
are presented by age groups < 5 years and ≥ 5 years.
Skewed data, such as the time to event outcomes, were
compared using the non-parametric Wilcoxon rank sum
test. The paper-based questionnaires were double-entered
and validated in EpiData version 3.1 software (The Epi-
Data Association, Odense, Denmark) and analysed in Stata
version 12.1 (Stata Corp, College Station, TX, USA).
Key procedures
Prior to the first study phase, all investigators and staff
involved in the study in each hospital/health centre par-
ticipated in a 3-day training on study procedures. La-
boratory technicians received a refresher course on thick
blood smear preparation/reading and, before the second
phase, a refresher course on haemoglobin (Hb) measure-
ment with the HemoCue 201 plus system (Angelholm,
Sweden). Simulated interviews were conducted to prac-
tice obtaining informed consent. Local principal investi-
gators took part in practical sessions on filling in the
case report forms (CRF). Nurses and doctors attended a
separate training on reporting serious adverse events
(SAE). Nurses also participated in piloting the time and
motion study tool, which included observing and timing
the activities related to drug preparation/administrationprior to the first data collection. Upon completion of the
first phase, hospital and health centre personnel involved
in the study convened in Kinshasa for a 2-day training
on preparing and administering injectable artesunate.
Job aids and training tools developed by MMV were
used for this training [9]. In addition, each site received
ten doses of injectable artesunate for training purposes,
allowing health care providers to become familiar with
the new drug prior to patient recruitment. Weekly
supervision visits to each site throughout the duration of
the study ensured regular monitoring of the study team.
Patient assessment
Demographic information and limited routine clinical
history data were collected for each patient and local
study physicians (hospitals) or nurses (health centres)
performed basic routine clinical assessments. A Giemsa-
stained thick blood smear was performed and examined
every 12 h during the first 24 h and then every 24 h until
negative or until patient discharge. For PCT calculations,
thick blood smears were later reread for quality control
by experienced microscopists at the KSPH, blinded to
the results of the first reading and to the RDT results.
Hb levels were systematically assessed with a HemoCue
201 plus + photometer (Angelholm, Sweden) during the
second study phase, at hospital admission, at discharge
and at follow-up visits on days 7, 14, 21, and 28. The
HemoCue testing resulted in a change in study protocol
because of reports of haemolytic anaemia following arte-
sunate treatment [10]. The results of that extension are
presented elsewhere [11]. To ensure the proper func-
tioning of the photometer, high and low Hb liquid con-
trols (HemoCue Eurotrol HemoTrol) were run weekly at
each site. Given the observational nature of the study,
laboratory tests were not systematically performed and
were left to the discretion of the physician or treating
nurse, except for parasitological tests required for inclu-
sion in the study and the Hb assessment during the sec-
ond phase. Time of admission, time of start and end of
parenteral treatment, and time to discharge were also
recorded for every patient during both phases.
Parenteral treatment was completed by administering
a full course of the recommended first-line, oral, com-
bination therapy AS-AQ or AL in the artesunate phase,
or with quinine tablets or the standard treatment prac-
ticed by the centre in the quinine phase. The first dose
of the oral treatment was administered at the health
facility in the presence of the nurse responsible. Subse-
quent doses were administered at home, according to
the instructions given to parents and guardians. Patients
were discharged at the discretion of the attending phys-
ician/nurse, after a final clinical assessment. During the
first study phase, patients were asked to return to the hos-
pital/health centre for follow-up 7 days after discharge to
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apy. In the second study phase, patients were asked to re-
turn on days 7, 14, 21, and 28 after discharge to assess the
clinical status and adherence to oral therapy and to deter-
mine their Hb levels at these time points.
Time and motion
The time and motion methodology consisted of 1) divid-
ing a process into key tasks, and 2) observing each task
to assess the average time required to perform it. The
sum of the average times spent on each task was used to
compute the total average time to complete the process.
In each of the three participating hospitals, an external
study nurse supervised the time and motion component
and was present throughout the study. In the five health
centres, the health centre personnel were responsible for
the measurements. Therefore, the number of patients
followed up was limited as a second nurse was not al-
ways available. Observed activities included: 1) pre-
administration tasks (preparation of all materials and
injectable solution, searching for the vein, setting the
infusion in case of quinine), 2) drug administration, and
3) all other activities related to patient management.
Observations were made by the nurses using digital
stopwatches and a checklist to record the time taken for
each task. Inter-observer agreement was not formally
assessed. Materials required for all tasks were also re-
corded on the same observer checklist and this informa-
tion was used later to calculate financial costs.
Cost of treatment component
A financial cost analysis was carried out from the pro-
vider’s perspective, accounting only for costs incurred by
the hospitals and the health centres. Complete unit cost
data on resources used were recorded for 386 patients
under quinine and for 333 patients under artesunate. To
estimate the mean unit cost, the 2014 average exchange
rate (USD 0.00107 to the Congolese Franc) was adopted
[12]. Health care costs were divided into four main cat-
egories: 1) drug costs (parenteral quinine and artesunate,
oral therapy), 2) diagnostic costs (blood smear), 3)
administration equipment costs (infusion set, IV solu-
tion, syringes), and 4) in-patient costs (consultation cost,
bed occupancy, blood transfusion, and nursing care).
Administration equipment, blood smear and parenteral
quinine unit costs were estimated from the hospital/
health centre price lists, as well as in-patient costs. The
full dose costs for both parenteral quinine and artesu-
nate were applied, since the recommendation given in
the study was to avoid re-using the drug once it was
opened, and hence partially used ampoules had to be
discarded. Artesunate was used in the 60-mg vial, the
WHO pre-qualified formulation at the time. Costs of
oral treatment with AS-AQ/AL were included in theanalysis despite being subsidized by the Global Fund to
Fight AIDS, TB and Malaria (GFATM) in the selected
health facilities. Costs of artesunate and of AS-AQ/AL
were obtained from the Management Sciences for Health
(MSH) International Drug Price Indicator Guide [13].
Additional treatments and diagnostic costs, other than
the parenteral drug and the thick blood smear, were not
included in the analysis. Specific costs associated with
co-morbidities, with the exception of blood transfusions
(severe anaemia), were not considered in the analysis
because they would have required a level of clinical
monitoring that was not possible in this study. In two
sites (referral hospital Saint Luc and Health Centre
Ngeba), a lump sum health care payment system was in
place, thus unit costs were unavailable. The decision was
made to reflect as closely as possible the local practice
and to generate nationally relevant data rather than
internationally, fully costed estimates. Hence, the lump
sum estimates were taken for this analysis. However, the
two sites were analysed separately to take these differ-
ences into account, since lump sums are likely to under-
estimate the full cost of treatment, especially if there is a
central subsidy by an external donor, as in the case of
these two facilities.
Results
Clinical assessment
A total of 749 patients were recruited from eight sites,
399 in the quinine group from October 2012 to January
2013 (study phase one), and 350 in the artesunate group
from April to July 2013 (study phase two). The quinine
group consisted of 248 (62 %) children between 2 and
59 months, and 151 (38 %) individuals aged 5 years and
above. The artesunate group consisted of 215 (61 %)
children between 2 and 59 months and 135 (39 %) indi-
viduals aged 5 years and above. The demographic and
baseline characteristics were similar for the two study
groups (Table 1). All patients tested positive for malaria,
either by thick blood smear or RDT on the day of inclu-
sion. Overall mortality was 2.8 % (21/749), with 3.8 %
for patients treated with quinine (15/399) and 1.7 % for
patients treated with artesunate (6/350) (p = 0.110). The
majority of deaths (13 of 21, 62 %) occurred within the
first 24 h after admission, of which nine of 15 were in
the quinine group (with two dying before receiving the
treatment) and four of six were in the artesunate group
(zero before receiving the treatment). Of the eight deaths
that occurred after 24 h, six occurred in the quinine
group and two in the artesunate group. Prostration was
the most frequent manifestation of severe malaria at ad-
mission in children between 2 and 59 months in the
quinine (204/248, 82 %) and artesunate groups (171/215,
80 %), as well as in individuals 5 years and above (122/
151, 81 % and 120/135, 90 %). Respiratory distress and
Table 1 Characteristics and clinical presentation of patients at recruitment
Quinine (N = 399) Artesunate (N = 350)
2–59 months (N = 248) >5 years (N = 151) 2–59 months (N = 215) >5 years (N = 135)
Sex
Female 122 (49 %) 72 (48 %) 115 (53 %) 71 (53 %)
Age 24 (7–53) 10 (5–48) 24 (7–48) 8 (5–48)
Medical history (past 30 days)
Other malaria episode 18 (7 %) 7 (5 %) 16 (7 %) 16 (12 %)
Fever (N = 398) 90 (37 %) 78 (52 %) 59 (27 %) 76 (56 %)
Pretreatment with anti-malarial 31 (12 %) 20 (13 %) 20 (9 %) 20 (15 %)
Other treatment(s) received 113 (46 %) 75 (50 %) 98 (46 %) 83 (61 %)
Other major health problem(s) 6 (2 %) 3 (2 %) 0 (0 %) 4 (3 %)
Episode of convulsion (N = 394) 34 (14 %) 10 (7 %) 13 (6 %) 11 (8 %)
Known hypersensitivity to other drugs 0 (0 %) 5 (3 %) 2 (1 %) 5 (7 %)
Signs and symptoms on admission
Fever 220 (89 %) 129 (85 %) 197 (92 %) 121 (90 %)
Fever before enrolment (days and range) 3 (2–4) 3 (2–5) 3 (1–7) 3 (1–7)
Vomiting 100 (40 %) 78 (52 %) 113 (53 %) 78 (58 %)
Coma 23 (9 %) 12 (8 %) 5 (2 %) 11 (8 %)
Reported convulsions 72 (29 %) 19 (13 %) 59 (27 %) 14 (10 %)
Blantyre coma score (8–24 months) 3 (2–5) − 4 (3–8) −
Glasgow coma score (>2 years) 10.5 (5–13) 10 (8–15) 7.5 (4–5) NA
Pallor NA NA 77 (36 %) 20 (15 %)
Jaundice 3 (1 %) 4 (3 %) 7 (3 %) 2 (1 %)
Shock 10 (4 %) 2 (1 %) 2 (1 %) 2 (1 %)
Respiratory distress 128 (52 %) 58 (38 %) 96 (45 %) 64 (47 %)
Severe anaemia (<5 g/dl) (N = 326 Q; 334 A) 8.1 (3 %) a 9.1 (2 %) a 15 (7 %) b 1 (1 %) b
Parasite count (per μl); geometric
mean (95 % CI)
17 068 (12 119-24 038) c 12 022 (7 040-20 527) c 22 289 (15 498-32 057) c 12 346 (7 812-19 511) c
Prostration 204 (82 %) 122 (81 %) 171 (79 %) 120 (89 %)
Urine colouration (N = 391) 2 (1 %) 2 (1 %) 10 (5 %) 8 (6 %)
Clinical examination on admission
Weight (kg and SD) 11.1 (3.0) 33.2 (17) 11.2 (4) 27.6 (15)
Temperature (°C and SD) (N = 398) 38.1 (1) 38.3 (1) 38.1 (1) 38.4 (1)
Pulse 125 (70–180) 102 (64–148) 119 (60–171) 94 (60–140)
Respiratory rate per minute 42.5 (28–72) 39.0 (24–60) 40 (24–72) 40 (20–58)
Co-morbidity 82 (34 %) 51 (34 %) 80 (37 %) 58 (43 %)
Data are summarized as numbers (%), median (90 % central range) or mean (SD)
NA not available
a Clinical assessment only
b HemoCue
c The initial parasitaemia was calculated only for those patients for whom the biological confirmation was done by thick blood smear
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in both groups. The total number of patients who re-
ceived a blood transfusion was 214 (29 %), with 128
(32 %) and 88 (25 %) in the quinine and artesunate
groups, respectively. Five per cent of the patients under
the quinine regimen had persistent symptoms at dis-
charge, compared to 3 % under the artesunate regimen(Table 2). A decrease in Hb levels at one of the follow-
up visits was a frequent SAE reported during the artesu-
nate regimen [11]. A 7-day oral quinine course was the
most frequently prescribed oral medication to complete
treatment after the initial injectable quinine regimen
(92 %), whereas AS-AQ was the most prescribed oral
medication (97 %) after injectable artesunate for all ages.
Table 2 Clinical examination at discharge
Quinine Artesunate
2–59 months
(N = 226)
>5 years
(N = 144)
2–59 months
(N = 208)
>5 years
(N = 131)
Weight (kg) 11.1 (3.0) 32.8 (16.7) 11.2 (4.3) 27.2 (14.9)
Temperature
(°C)
36.7 (0.5) 36.6 (0.5) 36.7 (0.4) 36.5 (0.4)
Pulse 100 (70–128) 90 (41–120) 90 (64–124) 85.4 (18.8)
Respiratory rate
per minute
35 (22–40) 28 (16–48) 31.8 (6.6) 29.2 (8.0)
Persistence of
signs at
discharge
12 (5.4 %) 6 (4.3 %) 7 (3.4 %) 4 (3.0 %)
Data are summarized as numbers (%), median (90 % central range) or
mean (SD)
Table 4 Personnel time (in minutes) required to complete pre-
administration tasks, by drug type
Quinine (N = 832) Artesunate (N = 795)
Material preparation 6 (2–18) Material preparation 4 (1–10)
Drug preparation 4 (1–14) Reconstitution 3 (1–8)
Search for the vein 5 (1–14) Dilution 2 (1–10)
Perfusion regulation 4 (1–10) Dose verification 2 (1–6)
− Search for the vein 3 (1–10)
Median and 90 % central range
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treatment and the reported number of tablets taken. Fol-
lowing injectable quinine and injectable artesunate, 236
(85 %) and 308 (99 %) patients fully adhered to the treat-
ment, respectively.
The time to discharge was slightly lower in the artesu-
nate group compared to the quinine group, with a me-
dian of two (90 % central range 1–9) versus three (1–9)
days, respectively (p <0.001). Given that mortality was
slightly higher in the quinine group, this would have led
to a shorter hospital stay but the effect would be min-
imal because of the low case fatality rate. The interval
between admission and start of parenteral treatment was
significantly shorter in the artesunate group compared
to the quinine group, two (0–15) versus three (0–20)
hours (p <0.001). The interval from beginning parenteral
treatment initiating oral treatment was slightly longer in
the artesunate group (45 (32–56) versus 39 (12–67)
hours in the quinine group, p <0.001). Parasite clear-
ance time was 23 (11–49) hours for artesunate versus
24 (10–82) hours for quinine (p <0.001) (Table 3).
Time and motion study
Administration times by task are shown in Tables 4 and
5. There was a reduction in the staff time required for
all tasks during the artesunate phase. The total medianTable 3 Key time intervals
Quinine Artesunate p-value
Time to discharge (days) 3 (1–9) 2 (1–9) p <0.001
Interval between admission and
beginning of parenteral
treatment (hours)
3 (0–20) 2 (0–15) p <0.001
Interval between beginning of
parenteral treatment and oral
treatment (hours)
39 (12–67) 45 (32–56) p <0.001
Parasite clearance time (hours) 24 (10–82) 23 (11–49) p <0.001
Median and 90 % central rangepersonnel time for pre-administration and patient man-
agement tasks was 33 (10–60) for artesunate and 36
(13–92) minutes for quinine. The median cumulative
staff time for observed drug pre-administration tasks
per patient per drug session was 13 (6–38) for artesu-
nate and 20 (7–50) minutes for quinine. Cumulative
median personnel time spent for patient management
was 9 (1–24) for artesunate and 12 (3–52) minutes for
quinine.Cost analysis
In hospitals and health centres, the mean (SD) total
costs per patient treated for severe malaria with inject-
able artesunate were USD 51.94 (16.20) and 19.51 (9.58);
and USD 60.35 (17.73) and 20.36 (6.80) with injectable
quinine. Costing details for individual study sites are
given in Table 6.Discussion
This study is the first to quantify key operational param-
eters in the management of patients with severe malaria
treated with injectable artesunate. Injectable artesunate
was superior to quinine for almost all of the parameters
assessed. Furthermore, from the provider’s perspective,
overall costs were lower for injectable artesunate in hos-
pitals and similar in health centres. The aim of the study
was to assess operational aspects rather than safety and
efficacy. However, there was no indication for any of the
outcomes obtained from available clinical charts that pa-
tients fared worse with injectable artesunate compared
to parenteral quinine, concurring with available data on
the efficacy and safety of the use of injectable artesunate
in the DRC [2].Table 5 Overall cumulative personnel time (in minutes)
Quinine Artesunate p-value
Overall personnel pre-
administration time
20 (7–50) 13 (6–38) p <0.001
Overall personnel patient
management time
12 (3–52) 9 (1–24) p <0.001
Overall personnel time 36 (13–92) 33 (10–60) p <0.001
Median and 90 % central range
Table 6 Mean cost (with SD) for treating one episode of severe malaria in patients admitted to hospitals and health centres in the
Democratic Republic of Congo
Hospital/Health
centre
Mean length of
stay, days (SD)
Blood
smear unit
cost
Mean injectable
drug cost
Mean oral drug
costa
Mean
administration
cost
Mean inpatient
cost
Mean total cost per
patient
QNN ART QNN ART QNN ART QNN ART QNN ART QNN ART QNN ART
Kimpese referral
hospital
7.12
(4.43)
6.26
(5.01)
2.94 2.94 0.45
(0.22)
7.72
(3.28)
0.66
(0.38)
0.48
(0.06)
1.89
(0.83)
1.39
(0.48)
49.56
(18.04)
47.25
(19.82)
61.58
(18.72)
59.57
(20.97)
Centre Hospitalier Roi
Baudouin
4.09
(3.41)
3.72
(2.17)
3.21 3.21 0.78
(0.17)
3.24
(1.51)
0.97
(0.30)
0.56
(0.21)
6.59
(1.56)
0.90
(0.83)
38.60
(12.99)
38.76
(8.32)
53.29
(7.86)
46.58
(8.55)
Hôpital St Luc
Kisantu
3.13
(1.06)
6.68
(4.00)
NA NA NA 3.87
(1.72)
0.70
(0.23)
0.50
(0.18)
NA NA NA NA 50.34
(9.98) b
55.44
(11.81) b
Health Centre CECO 3.96
(2.35)
4.28
(3.36)
1.07 1.07 0.57
(0.14)
7.19
(2.51)
1.00
(0.49)
0.48
(0.13)
2.10
(0.34)
1.62
(0.45)
40.28
(10.32)
41.62
(14.47)
32.53
(14.25) c
28.21
(9.41) c
Health Centre La
Famille
3.80
(1.54)
2.58
(1.50)
1.07 1.07 0.94
(0.43)
7.26
(3.95)
1.58
(0.59)
0.66
(0.30)
3.89
(1.59)
1.22
(0.45)
10.48
(3.63)
8.19
(3.21)
19.35
(4.46)
18.21
(5.02)
Health Centre Bita 2.18
(0.68)
1.99
(0.11)
1.07 1.07 1.49
(0.33)
7.30
(2.68)
1.99
(0.78)
0.49
(0.17)
6.48
(1.23)
1.51
(0.23)
6.71
(2.07)
6.39
(0.30)
21.97
(2.73)
16.56
(2.87)
Health Centre
Menkao
1.78
(0.97)
1.27
(1.34)
1.07 1.07 1.81
(0.72)
9.12
(5.09)
1.05
(0.45)
0.63
(0.24)
5.10
(1.19)
2.60
(0.73)
3.15
(1.29)
2.49
(1.76)
13.92
(2.59)
15.66
(5.84)
Health Centre Ngeba 4.6
(2.59)
2.7
(0.98)
NA NA NA 5.87
(1.95)
0.97
(0.30)
0.43
(0.04)
NA NA NA NA 6.86
(0.84) b
4.47
(0.10) b
In 2014 USD; NA not available
a Mean cost for oral quinine and AS-AQ
b Unit costs not available. Lump sum payment system. All exams and drugs other than anti-malarial are included. Patients pay a part of the total costs; the rest is
supported by a partner
c Among health centres, blood transfusion was only performed in CECO. To allow cost comparison with the other health centres, costs of blood transfusion were
not included in the total costs. Mean total costs for CECO under ART and QNN are USD47.47 (9.41) and USD51.79 (14.25) respectively if blood transfusion
is included
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was the need for comparative operational data between
the new regimen and the old regimen. Because many as-
pects in health services are setting-specific, it was
thought that the best controls would be the facilities
themselves. The strongest study design would include a
randomized concurrent control trial with enough health
facilities to account for inter-facility variability, however,
time and logistical reasons precluded such an approach
for the current study. The design outlined here was the
best suited to the Ministry of Health’s current plan for
scaling up artesunate. The operational parameters of
treating severe malaria are unlikely to be sensitive to
seasonal effects, and also unlikely to change much in a
given facility over time periods equal to that of the
study. Hence, although not randomized, this design
allowed a reasonable comparison of the two regimens in
real-world implementation settings. Although injectable
quinine has been the mainstay for treating severe mal-
aria for many years, there are virtually no existing data
in the literature quantifying the operational parameters
of interest.
In this study, patients admitted with severe malaria ex-
perienced a median delay of 3 h before receiving their
initial quinine dose compared to 2 h with artesunate
(Table 3). This time delay depended on several factors
that should be further investigated. In particular, it couldreflect the difficulties of promptly and safely administer-
ing quinine via IV. Although comparable in its prepar-
ation, quinine is a difficult drug to administer because of
its unfavourable safety profile; it requires correct dose
calculation, taking into account previous quinine treat-
ment to avoid overdosing and serious consequences for
the patient.
In the AQUAMAT trial [2], the risk of children dying
while waiting to receive quinine was almost four times
higher than the risk in children treated with artesunate.
This delay adds to the time needed for referral, during
which the condition of the patient can deteriorate [14].
In this study, 2 patients died before receiving quinine
compared to none in the artesunate group. Although
this delay is still critical for both regimens, it can be ex-
pected to decrease further for injectable artesunate as
skills and confidence are acquired through repeated ad-
ministration and preparation by health personnel.
The well-known difficulties in administering quinine
may also explain the difference observed in the time
interval between the beginning of the parenteral treat-
ment and the initiation of oral treatment. Lack of confi-
dence or uncertainty in reconstructing the history of
previous treatments with quinine could potentially limit
the number of doses a patient receives. According to the
national DRC directives on the treatment of severe mal-
aria [6], the number of doses of quinine administered
Ferrari et al. Malaria Journal  (2015) 14:226 Page 9 of 10should be minimized until the patient can tolerate an
oral medication. Under the artesunate regimen in this
study, the WHO’s recommendations of a minimum of
three injections during the first 24 h, irrespective of the
patient’s ability to tolerate oral medication were strictly
followed. This is one possible explanation for the pro-
longed time interval to the initiation of oral therapy.
The artesunate regimen achieved parasite clearance
faster than the quinine regimen, which likely accounts
for the shorter hospital stay. The reduction in median
hospital stay by a day reduces costs of malaria treatment
and minimizes socio-economic impacts on patients and
their families. This is especially important for poorer
and more vulnerable segments of the population.
The estimated costs of treating a patient with severe
malaria in this study are similar to those calculated in
previous studies [15, 16], although lower than those re-
ported by Kyaw et al., which used a more detailed cost
analysis approach [17]. The costs were highly variable,
depending on the level and type of facility (public, pri-
vate or missionary). The mean pooled estimate total cost
was found to be similar for artesunate compared to
quinine in health centres, USD 19.51 (9.58) and 20.36
(6.80), while lower in hospitals, USD 51.94 (16.20) to
USD 60.35 (17.73). Inpatient costs were the major driver
costs for the difference observed between hospitals and
health centres. Less standardized inpatient costs are
established by each hospital and health centre and take
into account a number of parameters, which include
cost of labour, and the organisation of the health service.
Since it was not possible to analyse all patient costs, par-
ticularly the cost related to supportive measures and the
presence of co-morbidities, the total treatment costs are
clearly underestimated. For the purpose of this study, a
new vial of quinine was used for every dose, but this is
not necessarily the case in the real world. As a result,
drug costs were likely overestimated. However, not all
sessions of drug preparation and administration were
included due to understaffed health centres and the in-
ability to reliably observe the most severe cases in need
of prompt treatment.
The results show that the overall time spent on pre-
administration tasks and on direct post-treatment pa-
tient care was slightly lower in the artesunate compared
to the quinine group. Although statistically significant,
this time difference is smaller than expected considering
that artesunate is easier to use. This could be explained
by the fact that health personnel had a limited time to
get used to preparing and administering artesunate be-
fore starting patient enrolment in the second phase.
Therefore, it could be that the overall difference in the
pre-administration times will increase over time, in
favour of artesunate. The overall personnel time spent
on patient care was lower with artesunate administrationcompared to quinine. This is likely to have resulted in
more time to care for other patients, leading to a posi-
tive effect on the overall quality of care. This was con-
sistent with health care providers’ higher satisfaction
when using artesunate, as described elsewhere (Ntuku
et al., personal communication).
Conclusions
This study provides for the first time descriptive evi-
dence of the effectiveness and practicability of using
injectable artesunate for treating severe malaria in hospi-
tals and health centres in the DRC. For most operational
and cost parameters, injectable artesunate was found to
be superior to injectable quinine. Combined with its
higher efficacy, these findings support the rapid switch-
over in the country. These findings also provide some
useful operational and cost data for national authorities
and for local health care managers involved in planning
the transition.
Training health personnel is obviously a key factor for
a successful transition, including a change in the atti-
tudes and behaviours of providers.
The MATIAS study has contributed further evidence
that injectable artesunate is a better treatment option
than injectable quinine for patients with severe malaria.
The findings suggest that transition to the new drug
should be accelerated as quickly as possible. The Minis-
try of Health of the DRC is currently scaling up the use
of injectable artesunate in the public sector, with the
support of the GFATM and the other partners, which
will enable 100 % coverage of in-patient cases within a
3-year period.
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